Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | ADH4 | P08319 | 1/20 | 0.41 |
| ▸ | ADH7 | P40394 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180229 | 0.79 | KMT2A (0.46) | CES2FAAHMEN1MAPK1KMT2A | |
| SCHEMBL3190699 | 0.79 | KMT2A (0.59) | CES2FAAHMEN1MAPK1KMT2A | |
| SCHEMBL837941 | 0.79 | MGAM (0.42) | ADH1BADH1CADH1A | |
| SCHEMBL4623923 | 0.74 | MGAM (0.38) | MEN1KMT2A | |
| SCHEMBL6067582 | 0.73 | CES2 (0.52) | CES2FAAHMEN1MAPK1KMT2A | |
| SCHEMBL10857678 | 0.72 | LMNA (0.43) | CES2FAAHMEN1MAPK1KMT2A | |
| SCHEMBL6560551 | 0.72 | CES2 (0.50) | CES2FAAHDGKA | |
| SCHEMBL653965 | 0.71 | KMT2A (0.56) | FAAHMEN1MAPK1KMT2A | |
| SCHEMBL11367762 | 0.71 | CES2 (0.50) | CES2FAAHDGKA | |
| SCHEMBL11372771 | 0.71 | CES2 (0.50) | CES2FAAHDGKATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207370-B2 | Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester | KANEKA CORPORATION (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20100022795-A1 | Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester | KANEKA CORPORATION (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-2067769-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE BETA-HYDROXY-ALPHA-AMINOCARBOXYLIC ACID ESTER | Kaneka Corporation (JP) | 2009-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022795-A1 | Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester | AADAT, ALAD, ALDH7A1 | CES2 2212/4885FAAH 811/4885ADH1B 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.